步长制药: 山东步长制药股份有限公司第五届董事会第二十七次会议决议公告

Core Points - The company held its 27th meeting of the 5th Board of Directors on July 8, 2025, with all 9 attending directors present, confirming the legality and validity of the meeting [1] - The company approved the participation as a limited partner in the Hainan Sanya Yuhai Growth Equity Investment Fund, with the investment amount decreasing from 614.5 million to 514.5 million, resulting in an increase in the company's shareholding percentage from 16.2734% to 19.4363% [1] - The company’s subsidiary, Shaanxi Modern Innovation Chinese Medicine Research Institute, will transfer 0.50% of its unpaid equity to another individual at a price of 0, while the company will hold 86.50% of the equity after the transfer [2] - The company will also not exercise its preferential right to acquire shares in its subsidiaries, maintaining a 90.00% equity stake in both Shandong Buchang Zhenze Pharmaceutical Technology and Shandong Buchang Guanyou Medical Devices after the transfers [3][4]